Activated K-Ras, But Not H-Ras or N-Ras, Regulates Brain Neural Stem Cell Proliferation in a Raf/Rb-dependent Manner

R. Hugh F. Bender1, Kevin M. Haigis2, David H. Gutmann1

Key words. neural stem cells • ras proteins • cell proliferation • raf kinases • retinoblastoma protein

ABSTRACT

Neural stem cells (NSCs) give rise to all the major cell types in the brain, including neurons, oligodendrocytes, and astrocytes. However, the intracellular signaling pathways that govern brain NSC proliferation and differentiation have been incompletely characterized to date. Since some neurodevelopmental brain disorders (Costello syndrome, Noonan syndrome) are caused by germline activating mutations in the RAS genes, Ras small GTPases are likely critical regulators of brain NSC function. In the mammalian brain, Ras exists as three distinct molecules (H-Ras, K-Ras, and N-Ras), each with different subcellular localizations, downstream signaling effectors, and biological effects. Leveraging a novel series of conditional activated Ras molecule-expressing genetically-engineered mouse strains, we demonstrate that activated K-Ras, but not H-Ras or N-Ras, expression increases brain NSC growth in a Raf-dependent, but Mek-independent, manner. Moreover, we show that activated K-Ras regulation of brain NSC proliferation requires Raf binding and suppression of retinoblastoma (Rb) function. Collectively, these observations establish tissue-specific differences in activated Ras molecule regulation of brain cell growth that operate through a non-canonical mechanism. Stem Cells 2014; 00:000–000

INTRODUCTION

Neural stem cells (NSCs) represent a self-renewing population found in neurogenic regions of the embryonic and adult brain [1, 2]. In addition to forming new NSCs (self-renewal and proliferation), these stem cells can also give rise to all the major cell types in the brain, including neurons, oligodendrocytes, and astrocytes, through multi-lineage differentiation [3-6]. Each of these cell fate decisions requires the activation of signaling pathways and transcriptional programs [3, 7-11]. In this regard, numerous potential regulatory mechanisms involving p53, Bmi1, sonic hedgehog (SHH), Notch, p27, REST/NSRF, epidermal growth factor receptor, and others [12-23], have been reported. While many of these signaling molecules are responsible for NSC growth and

1Department of Neurology, Washington University School of Medicine, St. Louis MO; 2Cancer Research Institute, Department of Medicine, Beth Israel Deaconess Medical Center, Boston MA

Address correspondence to: David H. Gutmann, MD, PhD, Department of Neurology, Washington University School of Medicine, Box 8111, 660 S. Euclid Avenue, St. Louis MO 63110. 314-362-7379 (Phone); 314-362-2388 (FAX); gutmann@neuro.wustl.edu (Email).

This work was funded by grants from the National Institutes of Health (NS065547-01 to D.H.G. and 1K01 CA118425 to K.M.H.). R.H.F.B. was supported by a National Institute of General Medical Sciences Training Grant (GM: 007067) and a pre-doctoral Young Investigator Award from the Children’s Tumor Foundation.

Received August 06, 2014; accepted for publication February 19, 2015

©AlphaMed Press
1066-5099/2015/$30.00/0

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/stem.1990
differentiation, it is not clear which ones are important for the pathogenesis of diseases characterized by abnormal brain NSC function.

A number of neurodevelopmental disorders, including neurofibromatosis type 1 (NF1), Costello syndrome, and Noonan syndrome, are caused by mutational activation of the Ras proto-oncogene [24-27]. Specifically, some individuals with Noonan syndrome [OMIM 218040; 613224] harbor germline activating mutations in the K-RAS or N-RAS genes, while activating H-RAS mutations have been reported in individuals affected with Costello syndrome [OMIM 613224]. Norman, small GTPase proteins, like Ras, act as molecular switches by alternating between active, GTP-bound and inactive, GDP-bound states [28]. However, in Costello and Noonan syndrome, these germline mutations result in Ras proteins, which are locked in the active GTP-bound form, leading to unchecked Ras pathway hyperactivation.

Ras exists as three separate molecules (H-Ras, K-Ras, and N-Ras). Despite 85% amino acid sequence similarity, the specific functions of each Ras molecule are dictated by distinct C-terminal 25-amino acid residues within the unique hypervariable regions (HVRs). While these HVRs contain CAAX-box motifs which are isoprenylated to allow for Ras targeting to the plasma membrane (PM) [29], differential palmitoylation directs their trafficking to the PM via the Golgi (H-Ras, N-Ras) or other, unknown mechanisms (K-Ras) [30, 31]. This differential processing directs the Ras molecules to distinct domains within the PM [32], and is thought to underlie their differential capacities to signal to downstream effector proteins in different cellular contexts [29, 33, 34].

Based on these potential differences, we hypothesized that activated H-Ras, K-Ras, and N-Ras expression, as observed in the Noonan and Costello neurogenetic disorders, may differentially regulate NSC growth and differentiation. Using a combination of in vivo and in vitro approaches, we demonstrate that controlled expression of activated K-Ras, but not H-Ras or N-Ras, increases brain NSC proliferation without altering multi-lineage differentiation. Moreover, activated K-Ras controls brain NSC growth in a Raf-dependent, but Mek-independent manner, through binding and inhibition of retinoblastoma protein (Rb) function.

**Materials and Methods**

**Mice.** Activated H-Ras, K-Ras, or N-Ras allele expression was induced in NSCs in vivo by intercrossing BLBP-Cre [35] mice with mice containing Lox-Stop-Lox (LSL)-H-RasG12V (Supporting Information Fig. S1; generated by Dr. Kevin Haigis), LSL-K-RasG12D [36], or LSL-N-RasG12D [37] constructs knocked into the respective Ras locus. All mice were maintained on a C57Bl/6 background in accordance with approved animal studies protocols at Washington University.

**Immunohistochemistry.** Brain tissues were collected at postnatal day 18 (PN18). Prior to tissue harvesting, mice were intracardially perfused with Ringer’s solution containing lidocaine and heparin followed by 4% paraformaldehyde. Tissues were post-fixed overnight in 4% paraformaldehyde and then in 70% ethanol overnight before embedding. Paraffin-embedded tissues were sectioned at 6μm thickness using a Leica RM2125 RT5 microtome (Leica Microsystems Inc., Buffalo Grove, IL). Antigen retrieval and appropriate primary antibodies (Supporting Information Table S1) were applied overnight at 4°C in immunohistochemistry (IHC) diluent (1% milk, 2% bovine serum albumin, 2% goat serum in TBS-Tween). Tissues were then incubated with species-appropriate horseradish peroxidase-conjugated secondary antibodies (Vector Laboratories, Burlingame, CA) in IHC diluent. Photomicrographs of the pons (Supporting Information Fig. S2) were acquired on a Nikon Eclipse E600 light microscope (Nikon Instruments Inc., Melville, NY) equipped with a Leica EC3 camera. Six to ten mice were collected per genotype along with appropriate matched littermate controls.

**Neural Stem Cell (NSC) Culture.** NSCs were generated from PN1 brainstems, as previously reported [38]. Briefly, dissociated brainstem tissue was cultured for five days in NSC-selective media supplemented with 1% N2 (Life Technologies), 2% B27 (Life Technologies), 20ng/mL fibroblast growth factor (FGF) (Sigma-Aldrich, St. Louis, MO) and 20ng/mL epidermal growth factor (EGF) (R&D Systems, Minneapolis, MN) in ultra-low attachment dishes (Corning, Corning, NY). Expression of activated H-Ras, K-Ras, or N-Ras molecules was induced in NSCs following Ad5-Cre (University of Iowa Gene Transfer Vector Core, Iowa City, IA) infection. Ad5-LacZ-infected NSCs served as controls. Ras activity was quantified in 750-1000μg of NSC lysates using commercially-available Raf1-Ras binding domain (RBD) affinity chromatography assay kits according to the manufacturer’s
instructions (Millipore, Billerica, MA). All NSC assays were performed on NSCs maintained in culture for fewer than three passages.

**NSC Growth.** NSC growth was assessed by direct cell counting following the seeding of 5,000 NSCs (in triplicate) in 24-well ultra-low attachment dishes (Corning) containing NSC media. Cells were trypsinized and counted using a hemocytometer after five days in culture. Each experiment was repeated at least three times using NSCs harvested from three independently-generated litters. For the immunocytochemistry experiments, neurospheres were collected after five days in culture, washed twice in PBS, and fixed for 30 minutes in 4% paraformaldehyde. Neurospheres were then dehydrated in 30% sucrose for at least 24 hours prior to embedding in OCT mounting media (Sakura Finetek, Torrance, CA) and freezing at -80°C. All frozen embedded neurospheres were cut into 10µm-thick sections on a Reichert-Jung Cryocut 1800 cryostat (Reichert Technologies, Depew, NY). Primary antibodies (Supporting Information Table S1) were applied overnight at 4°C in IF diluent. Tissues were subsequently incubated with species-appropriate AlexaFluor® 488 or 568 secondary antibodies (Life Technologies) in IF diluent and counterstained with DAPI. At least eight neurospheres of similar diameter and cell number were imaged per sample and compared to LacZ-infected control cells.

**In Vitro NSC Differentiation.** Differentiation was assessed by seeding 150,000 NSCs in triplicate onto 24-well plates coated with 50µg/mL poly-D-lysine (Sigma-Aldrich) and 10µg/mL fibronectin (Life Technologies) in NSC media supplemented with 1% N2, 2% B27, and 1% fetal bovine serum. After six days in culture, adherent cells were fixed for 15 minutes in 4% paraformaldehyde and stained overnight at 4°C with appropriate primary antibodies (Supporting Information Table S1) in PBS containing 2% goat serum. Cells were next incubated with species-appropriate AlexaFluor® 488 or 568 secondary antibodies (Life Technologies) in PBS with 2% goat serum and counterstained with DAPI. For the EdU studies, 20µM 5-ethyl-2'-deoxyuridine (EdU; Life Technologies) was added to the culture media 3 hours prior to fixation. EdU was detected using the Click-IT® EdU Assay Kit (Life Technologies) prior to immunocytochemistry staining according to manufacturer’s protocol. Each experiment was repeated at least three times using NSCs harvested from three independently-generated litters.

**Flow Cytometry Analysis.** Neurospheres were trypsinized and fixed overnight in 50% ethanol in PBS containing 0.02% IGEPA (Sigma-Aldrich). Following fixation, cells were washed three times in PBS prior to trypsinization (0.003% trypsin type-II [Sigma-Aldrich] in DNAse solution (0.1% IGEPA, 0.05% spermene tetrahydrochloride [Sigma-Aldrich] in 3.9mM sodium citrate buffer)) for 10 minutes at room temperature. Cells were subsequently incubated for 10 minutes at room temperature in trypsininhibitor type-O [Sigma-Aldrich], 0.001% RNase A [Sigma-Aldrich] in DNA analysis solution) prior to staining with 0.02% propidium iodide [Sigma-Aldrich] solution containing 0.015% spermene tetrachloride in DNA analysis solution for 10 minutes at room temperature. Apoptosis was measured using trypsinized neurospheres. Live cells were stained for annexin V and propidium iodide using an Annexin V-FITC Apoptosis Detection Kit (Abcam, Cambridge, MA) according to manufacturer’s protocol. All samples were quantitated on a Beckton Dickinson FACScan machine (Beckton Dickinson, Franklin Lakes, NJ) using FlowJo acquisition and analysis software (TreeStar Inc., Ashland, OR).

**Western Blotting.** NSCs were incubated in NSC media without B27, N2, EGF, and FGF growth supplements for two hours prior to a brief PBS wash and centrifugation. Cell pellets were lysed in cold lysis buffer (20mM Tris [pH 7.5], 10mM EGTA, 40mM β-glycerophosphate, 1% NP40, 2.5mM MgCl₂, and 2mM sodium orthovanadate) supplemented with aprotonin (1.4 µg/mL), leupeptin (1 µg/mL), and phenylmethanesulfonylfluoride (PMFS, 1mM) protease inhibitors) for protein quantitation using the Pierce BCA Protein Assay Kit (Thermo Fisher). The resulting cell lysates (20µg) were separated by SDS-PAGE followed by transfer to polyvinylidene difluoride (PVDF) membranes (Immobilon, Fisher Scientific). Membranes were blocked with 5% milk in 1x TBS-Tween prior to overnight incubation at 4°C with appropriate primary antibodies (Supporting Information Table S2). Detection was achieved using species-appropriate HRP-linked secondary antibodies (Cell Signaling, Danvers, MA) and enhanced chemiluminescence imaging (Bio-Rad Laboratories, Hercules, CA) using the ChemiDoc-It Imaging System (UVP, Upland, CA).

**Pharmacological Inhibition Studies.** The minimum effective inhibitor drug concentrations required to reduce K-Ras* NSC signaling activity to the levels observed in control NSCs were empirically determined by dose escalation experiments (data not shown). Using these doses, NSCs were treated with either 6.5µM GGTI-286 (Millipore), 200nM AZ628 (Selleck Chemicals, Houston TX), 2nM PD0325901 (Selleck Chemicals), 50nM MEK162 (Selleck Chemicals), 50nM AZD0530 (Selleck Chemicals), 20µM SB203580 (Selleck Chemicals), or 5µM RRD-251 (Sigma-Aldrich) for five days in culture. DMSO treatment served as a vehicle control.

**Dominant-Negative K-Ras Inhibition.** Dominant-negative K-Ras (dnK-RasS17) in the MSCV retroviral plasmid vector pSRα-IREs-GFP [39] was used to generate virus in human embryonic kidney 293T cells. MSCV-IREs-GFP served as control virus. Successful infection was confirmed by GFP expression in both control and dnK-RasS17-infected NSCs (Fig. 6C, Supporting Information Fig. S5B).

**Immunoprecipitation.** Raf-1 immunoprecipitation was performed using whole cell lysates in binding buffer containing 20mM HEPES (pH 7.9), 40mM KCl, 1mM MgCl₂, 0.1mM EGTA, 0.1mM EDTA, 0.1mM dithiothreitol, 0.1 NaF, 0.1mM Na₃VO₄, 0.5% IGEPA, and 3mg/mL BSA. Total protein (500µg) in 400µl of binding
buffer was pre-cleared with 30μl agarose protein G beads (Cell Signaling) for 2 hours at 4°C on a rotor. After removing the beads, lysates were incubated with Raf-1 monoclonal antibodies (Millipore, Supporting Information Table S1) overnight at 4°C on a rotor. Following the addition of agarose beads for an additional 2 hours, the beads were washed three times in 500μl binding buffer, boiled in 20μl 4x Laemmlli buffer (Bio-Rad Laboratories), and separated on 8% polyacrylamide gels for Western blotting. Raf-1 pull-down was confirmed by blotting with a different Raf-1 antibody (Cell Signaling, Supporting Information Table S2).

**Data Analysis.** Tissue and cell staining images were quantitated using ImageJ version 10.2 image analysis software (National Institutes of Health). The Grubbs outlier test was used to determine statistical outliers, and statistical significance (*p<0.05, **p<0.01, ***p<0.001) determined using an unpaired, two-tailed Student’s t-test and GraphPad Prism 5 software (GraphPad Software, La Jolla CA).

**RESULTS**

**Activated NSC K-Ras expression leads to increased astrogliogenesis in vivo.** To define the impact of activated Ras expression on NSC function in vivo, we leveraged BLBP-Cre mice to target activated Ras molecule expression to brain ventricular zone NSCs capable of giving rise to neurons, oligodendrocytes, and astrocytes in vivo (multi-lineage differentiation) [35]. This specific Cre driver strain was chosen, since Ras activation in nestin+ cells (nestin-Cre mice) is likely to result in embryonic lethality due to a defect in cardiac vessel septation [40]. Moreover, we have previously employed this particular BLBP-Cre strain to examine the impact of neurofibromatosis-1 loss on gliogenesis in vivo [35].

The expression of each individual activated Ras allele was accomplished using mice in which an oncogenic version was knocked into the endogenous Ras locus. Specifically, these RasLS[H-RasLS-G12V], RasLS[SL-G12D], or N-RasLS[SL-G12D] mice contain a transcriptional stop element flanked by LoxP sites (Lox-Stop-Lox [LSL]) that prevents expression of the mutationaly-activated Ras alleles in the absence of Cre expression. Following Cre-mediated recombination, mutationaly-activated Ras (Ras*) is expressed from its endogenous promoter.

Since the majority of neuronal and non-neuronal cell fate specification occurs within three weeks following birth, we examined the consequence of activated Ras molecule expression on brain cell development at postnatal day 18 (PN18). At PN18, there was a greater percentage of astrocytes in K-Ras*BLBP, but not H-Ras*BLBP or N-Ras*BLBP, mice relative to littermate controls using GFAP (1.8-fold) and S100β (1.2-fold) astrocyte antibodies (Fig. 1A, 1B). In contrast, there was no change in APC+ oligodendrocytes (Fig. 1C) or NeuN+ neurons (Fig. 1D) or differences in brain or body weights across the three Ras genotypes relative to controls (Supporting Information Fig. S3). These data demonstrate that activated K-Ras, but not H-Ras or N-Ras, expression in NSCs leads to the generation of more astrocytes in vivo.

**Activated K-Ras expression does not alter NSC astrocyte differentiation.** To determine whether activated K-Ras expression alters brain NSC astrocyte differentiation, we employed neurosphere cultures generated from brainstem of PN1 pups infected with adenovirus expressing either LacZ (control cells, CTL) or Cre recombinase (activated H-Ras, K-Ras, or N-Ras, denoted H-Ras*, K-Ras*, or N-Ras*, respectively). Raf1-RBD affinity chromatography confirmed that Ras activation was comparably increased after Ad5-Cre infection (Fig. 2A). Following in vitro differentiation of these NSCs over six days in adherent culture, only K-Ras*-expressing NSCs exhibited increased numbers of GFAP+ astrocytes (1.8-fold) relative to controls (Fig. 2B). Importantly, K-Ras*-expressing NSC cultures also showed an increase in the total number of DAPI+ cells (1.8-fold) compared to control cells (Fig. 2C). The increase in GFAP+ cells proportional to total DAPI+ cells resulted in no change in the percentage of GFAP+ cells compared to controls (Fig. 2D), indicating that activated K-Ras expression does not directly change NSC astrocyte differentiation.

To determine whether the increase in astrocyte numbers following K-Ras* expression reflected an increase in the NSC pool during differentiation (EdU incorporation), we examined differentiating cells at both early (one day post-plating) and late (five days post-plating) time points (Fig. 3A). In addition to EdU incorporation, neuroglial lineage antibodies for NSCs (Sox2) and astrocytes (GFAP) were used to quantify changes in both populations. After one day in culture, K-Ras*-expressing cells were proliferating 7.4-fold more than their control counterparts (Fig. 3B). These proliferating cells were exclusively Sox2+ NSCs, and not GFAP+ astrocytes (Fig. 3C). At this time, there was no change in the percentage of Sox2+ NSCs; however, a smaller percentage of K-Ras*-expressing cells were GFAP+ astrocytes relative to control cells (Fig. 3D). After five days in culture, K-Ras* expressing cells were still proliferating 2.2-fold more than controls (Fig. 3E), however, there was no difference in proliferating NSCs or astrocytes (Fig. 3F). While a higher percentage (1.6-fold) of K-Ras*-expressing cells were Sox2+ NSCs relative to control cells, there was no difference in the percentage of GFAP+ astrocytes in either K-Ras* or control cell populations (Fig. 3G). Together, these data demonstrate that activated K-Ras expression increases the NSC pool, rather than driving NSCs towards astrocyte differentiation.

**Activated K-Ras expression increases NSC proliferation in vitro.** To determine whether the individual Ras* molecules differentially increase NSC growth in vitro, we directly counted NSCs after five days in culture. Similar to the above findings, 2.3-fold more K-Ras*, but not H-Ras*, or N-Ras*, expressing NSCs were observed relative to controls (Fig. 4A). At this time, K-Ras*, but not H-Ras* or N-Ras*, expressing neurospheres had a 1.6-fold increase in the percentage of Ki67+ proliferating cells (Fig. 4B). Following continued in vitro passage, this
K-Ras*-expressing NSC growth advantage was sustained for approximately five passages, after which, both control and K-Ras*-expressing NSCs failed to survive (Supporting Information Fig. S4). To determine whether the increased K-Ras* NSC growth reflected increased proliferation or decreased cell death, flow cytometry was employed. Using propidium iodide to analyze cellular DNA content, fewer K-Ras*-expressing NSCs were in the pre-cycling G0/G1 phase (~4.6%) of the cell cycle relative to controls, while more K-Ras*-expressing NSCs were in S phase (~3.6%) and G2/M phase (~2.6%) (Fig. 4C, 4D). Finally, using annexin-V staining to identify cells undergoing programmed cell death (apoptosis), no differences were found between live and apoptotic K-Ras*-expressing and control NSCs (Fig. 4E, 4F). Collectively, these data are consistent with a model in which activated K-Ras expression increases NSC proliferation to expand the NSC pool and result in a proportional increase in astrocytes following differentiation (Fig. 4G).

**K-Ras**<sup>GRIP</sup> **mice have more Sox2**<sup>+</sup> **and Olig2**<sup>+</sup> **progenitor cells.** Based on the above *in vitro* findings, we sought to determine whether a similar expansion of NSCs was observed within the developing mouse brain *in vivo*. Specifically, two progenitor cell populations (Sox2<sup>+</sup> NSCs, Olig2<sup>+</sup> glial-restricted progenitor cells) at two different developmental time, shortly after K-Ras<sup>GRIP</sup> activation (E12.5) and at birth (PN1). In the E12.5 hindbrain (the future postnatal pons), K-Ras<sup>GRIP</sup> mice harbored 2-fold more Sox2<sup>+</sup> NSCs per unit area (0.1mm<sup>2</sup>) relative to littermate controls (Fig. 5A). At PN1, no difference in the numbers of Sox2<sup>+</sup> NSCs was observed in the brainstems of K-Ras<sup>GRIP</sup> versus littermate control mice (Fig. 5B). However, at PN1, there was a 1.9-fold increase in the numbers of Olig2<sup>+</sup> glial-restricted progenitor cells following activated K-Ras expression (Fig. 5C). Together, these data demonstrate that activated K-Ras expression in NSCs results in an early expansion of progenitor cells, which likely underlies the increase in astrocytes observed in the K-Ras<sup>GRIP</sup> mouse brainstem at PN18.

**Activated K-Ras expression increases NSC proliferation in a Raf-dependent, but Mek-independent, manner.** Using a Raf-RBD assay, K-Ras activation activity was ~30-fold higher in K-Ras*-expressing NSCs relative to controls (Fig. 6A). Based on this level of K-Ras activation, pharmacological inhibitor studies were employed to define the downstream signaling pathway responsible for activated K-Ras (K-Ras*) control of NSC proliferation. We experimentally defined the minimal doses of pharmacological inhibitors required to reduce K-Ras* effector pathway hyperactivation to WT control levels (data not shown). First, we confirmed that K-Ras activation was required for K-Ras*-expressed NSC hyperproliferation using the GGTI-286 geranylgeranyltransferase inhibitor. Following GGTI-286 (6.5μM) treatment, the hyperproliferation of K-Ras* NSCs was reduced to that of control cells, as measured by direct cell counting (Fig. 6B, Supporting Information Fig. S5A). Western blot analysis of the Ras downstream effector protein Erk revealed reduced p-Erk activity following GGTI-286 inhibiton. Similarly, infection of K-Ras* NSCs with dominant-negative K-Ras (dnK-Ras<sup>N17</sup>; [39]) reduced K-Ras* NSC hyperproliferation to that of control cells, as measured by direct cell counting (Fig. 6C, Supporting Information Fig. S5B).

Second, after inhibition with the pan-Raf inhibitor AZ628 (200nM), K-Ras*-induced NSC hyperproliferation was attenuated to that of control cells (Fig. 6D, Supporting Information Fig. S5C). As previously reported, increased Erk activation was observed following Raf inhibitor treatment [41], thus precluding independent confirmation of AZ628 Raf inhibition. Consistent with Ras- and Raf-mediated activation, increased Erk activation was observed in K-Ras*-expressing NSCs (Fig. 6E).

To determine whether Raf/Mek signaling was responsible for K-Ras*-induced NSC hyperproliferation, K-Ras*-expressing NSCs were treated with the PD0325901 (PD901; 2nM) or MEK162 (50nM) Mek inhibitors. Treatment with either PD901 or MEK162 reduced Erk hyperactivation, but did not attenuate K-Ras*-mediated NSC hyperproliferation (Fig. 6F, 6G, Supporting Information Fig. S5D, S5E).

These unexpected results prompted a detailed examination of other potential Raf effector proteins. While we observed no change in Akt, Jnk, PKC-ζ, PKC-ε, Rac, β-catenin, and Yap activity, Src and p38MAPK were hyperactivated (increased Src<sup>Y410</sup> and p38MAPK<sup>T202/Y182</sup> phosphorylation, respectively) in K-Ras*-expressing NSCs compared to controls (Supporting Information Fig. S6A, S6B). However, pharmacologic inhibition of Src (50nM AZD0530) or p38MAPK (20μM SB203580) activity did not reduce K-Ras*-induced NSC hyperproliferation (Supporting Information Fig. S6C, S6D). Similarly, neither GGTI-286 (Ras inhibitor) nor AZ628 (Raf inhibitor) treatments reduced Src or p38MAPK hyperactivation (Supporting Information Fig. S6E). Collectively, these data demonstrate that K-Ras* expression increases NSC proliferation in a Raf-dependent, but Mek-, Src-, and p38MAPK-independent, manner.

**Raf-1 inhibition of Rb is responsible for activated K-Ras-induced NSC hyperproliferation.** To determine how K-Ras* regulates NSC proliferation, we focused on potential Raf-dependent mechanisms. Previous studies have shown that Raf-1 (c-Raf) directly binds the retinoblastoma tumor suppressor protein (Rb) to relieve Rb-mediated suppression of cell cycle progression [42]. We found that endogenous Rb bound to Raf-1 in K-Ras*-expressing NSCs, as assessed by Raf-1 immunoprecipitation (Fig. 7A). Based on these findings, we employed a small peptide inhibitor, RRD-251, previously shown to disrupt the Raf-1/Rb interaction [43, 44], to demonstrate that this particular interaction was required for K-Ras*-mediated NSC hyperproliferation. Treatment of K-Ras*-expressing NSCs with RRD-251 (5 μM) reduced K-Ras*-induced NSC hyperproliferation to control levels (Fig. 7B, Supporting Information Fig. S7). Together, these data establish a new model for K-Ras* regulation of NSC proliferation, in which K-Ras activation of Raf leads to Rb binding and inhibition, and leads
to increased G0/G1 to S transition and proliferation (Fig. 7C).

**DISCUSSION**

Despite the central role of Ras in regulating embryonic development, the three Ras molecules do not equally impact on this process. For example, bi-allelic K-Ras deletion in mice results in lethality between 12 and 14 days of gestation, due to brainstem defects, hematopoietic abnormalities, and organ failure [45, 46]. In contrast, H-Ras or N-Ras deletion, either separately or in combination, does not impair normal embryonic development, resulting in healthy adult mice [47, 48]. These differential effects are further highlighted by observations made in human neurogenetic disorders characterized by germline activating mutations in the three RAS genes (collectively termed “RASopathies”). In these RASopathies, H-Ras mutations [26] have been reported in Costello syndrome, whereas individuals with Noonan syndrome harbor K-Ras mutations [27], each with varying neurocognitive delays and learning disabilities. The importance of differential Ras molecule activation is additionally underscored by the finding of oncogenic K-Ras, but not H-Ras or N-Ras, mutations in pediatric brain tumors [49, 50].

Herein, we demonstrate that activated K-Ras, but not H-Ras or N-Ras, molecule expression increases the proliferation of brain NSCs. While no prior studies have systematically compared the consequences of expressing these three individual activated Ras molecules in the brain, previous work in other tissue types has revealed divergent functions for each of these proteins. In neural crest-derived hematopoietic cells, activated N-Ras is the primary regulator of cell self-renewal, proliferation, and cell fate decisions [51-54], whereas activated K-Ras primarily drives cell growth in endoderm-derived tissues (lungs, colon) [36, 55]. Similarly, in endoderm-derived stem cells, overexpression of active H-Ras[G12V] promotes cell differentiation and suppresses cell growth, in contrast to K-Ras[G12V] overexpression that promotes stem cell proliferation and inhibits cell differentiation [56]. Moreover, K-Ras[G12D] expression increases the proliferation of an intestinal stem cell population, whereas N-Ras[G12D] expression increases the resistance of these cells to apoptosis without changing cell proliferation [37]. Lastly, K-Ras[G12D] expression has also been reported to cause bronchoalveolar stem cell hyperproliferation in the lung [55]. Taken together, these studies identify K-Ras* as a potent driver of progenitor cell proliferation, which is consistent with our finding that only activated K-Ras expression promotes brain NSC proliferation.

Deregulated RAS signaling is an important step in cancer initiation, with activating RAS mutations implicated in 30% of all cancers [57]. Of particular relevance to the current study is the prevalence of activating K-RAS gene mutations (22% of all cancers) relative to mutations in either the H-RAS or N-RAS genes (11% of all cancers combined). Although our study focused on the developmental implications of activated Ras expression on NSC function, the increased NSC proliferation observed following K-Ras* expression prompted us to examine mice for tumor formation. In a small number of K-Ras*G12D mice (n=3) aged to 8 weeks of age, all developed squamous cell papillomas of the vagina/anus. Complete necropsy did not reveal any pathology indicative of a brain tumor (data not shown). These findings are consistent with previous reports demonstrating that oncogenic Ras expression leads to increased proliferation without subsequent tumor formation. In these studies, expression of the same K-Ras[G12D] allele in colonic epithelial cells resulted in hyperplasia, but not neoplasia, of the intestinal epithelium [37]. It was only when K-Ras* expression was combined with loss of Apc expression did colonic tumors form. Similarly, K-Ras* expression alone in nestin+ or GFAP+ neural stem/progenitor cells in the brain was not sufficient for tumor formation [51, 58], yet led to glioblastoma when combined with constitutively-active Akt expression [59]. Given the high level of sequence similarity between the three Ras molecules and their capacity to signal to a similar subset of downstream effector proteins, it is striking that these molecules have such divergent functions. However, these differences are conferred by unique 25-amino acid, C-terminal HVRs. During post-translational processing, the Ras molecules are first prenylated by farnesyltransferase, which allows for trafficking to the endoplasmic reticulum [60, 61]. After this step, Ras molecule post-translational processing diverges: K-Ras becomes more highly methylated than its H-Ras and N-Ras counterparts [30]. H-Ras and N-Ras are then palmitoylated and trafficked to the PM through the Golgi apparatus while methylated K-Ras is trafficked to the PM independent of the Golgi [31, 58]. The exact mechanism responsible for mediating K-Ras trafficking is unknown, however, its transport has been shown to be dependent on a polybasic, lysine-rich portion of the K-Ras HVR not found within the HVRs of H-Ras or N-Ras [62]. Following its PM localization, each Ras molecule occupies a different microdomain: N-Ras is found in lipid raft domains, while K-Ras localizes to non-lipid raft portions of the membrane [32, 63]. H-Ras occupies lipid raft domains when inactive, but translocates to non-lipid raft membrane upon activation (in areas distinct from those occupied by K-Ras) [32, 64]. In addition, H-Ras and N-Ras are also capable of signaling to downstream effectors from the Golgi, a capability not shared by K-Ras [65, 66]. Collectively, the divergent processing and localization of the Ras molecules likely account for their capacities to signal to different subsets of downstream proteins to generate different biological outcomes [33, 34].

Ras/Raf signal transduction most commonly operates through Raf activation of Mek1/2 [67-69]. In striking contrast to this canonical signaling mechanism, we demonstrate that activated K-Ras expression increases brain NSC proliferation in a Raf-dependent manner that
operates independent of Mek. Precedent for Mek-independent Ras/Raf growth control derives from several studies performed in numerous different cell types. First, Raf-1 overexpression has been shown to increase cell survival by inhibiting ASK-1 function in the presence of the Mek pharmacological inhibitors PD98059 and U0126 [70]. Second, K-Ras*-expressing DLD-1 cells continue to proliferate despite treatment with the Mek inhibitor CI-1040. Proliferation of these cells was only inhibited in the presence of the Raf inhibitor AZ628 [37]. Third, protein binding discovery studies have revealed several other potential Raf binding partners, including the 14-3-3-zeta protein, which modulates Raf signaling during cell stress through its association with keratin 8/18 [71, 72]. Fourth, both B-Raf and Raf-1 associate with PKC-theta to inactivate the pro-apoptotic Bcl-2 family protein BAD and increase cell survival [73]. While these studies collectively identify a role for Raf in cell growth, we found that K-Ras*-dependent brain NSC hyperproliferation depends on the productive interaction between Raf-1 and the retinoblastoma (Rb) cell cycle regulator [42]. The Rb tumor suppressor protein prevents cell cycle progression by inhibiting the expression of the E2F transcription factors to prevent DNA synthesis. Upon growth factor stimulation, this inhibition is relieved, allowing cells to progress through the cell cycle. Using genetic and biochemical techniques to alter Ras expression in the presence or absence of Rb expression, early work established a hierarchy for Ras/Rb/cell cycle regulation, whereby Ras inhibition of Rb function led to increased proliferation [74, 75]. The mechanism underlying this Ras/Rb connection was identified when direct binding between Raf-1 and Rb was revealed [42]. Consistent with previous studies demonstrating that the RRD-251 small peptide interrupts this interaction and block tumor cell growth [42-44, 76-78], we found that K-Ras*-induced NSC hyperproliferation depended on Raf/Rb binding and inhibition of Rb function. In summary, using a novel collection of conditional Ras genetically-engineered mouse strains and derivative NSCs, we establish differential effects of the three activated Ras molecules on brain NSC proliferation. Moreover, the elucidation of a non-conventional mechanism underlying Ras/Raf-mediated NSC growth control suggests additional determinants relevant to the study of diseases characterized by de-regulated RAS function. Future studies characterizing differences in Ras molecule function in disease-pertinent models will be critical to further defining and ultimately treating these disorders.

CONCLUSION AND SUMMARY

To our knowledge, this is the first study to compare the impact of regulated expression of all three activated Ras alleles on brain NSC function using identically-constructed genetically-engineered mouse strains. Using this approach, activated K-Ras, but not H-Ras or N-Ras, expression increases NSC proliferation without altering astrocyte differentiation. Additionally, K-Ras* regulates NSC proliferation in a Raf-dependent manner, not involving the Raf downstream effectors Mek and Erk. Instead, K-Ras* increases brain NSC proliferation through Raf inhibition of the Rb tumor suppressor protein, thereby releasing Rb-mediated suppression of cell cycle progression. This comparison of the activated Ras molecules will be relevant for future studies that aim to interpret the differential contributions of the Ras molecules to neurodevelopmental disorders resulting from activated Ras molecule expression.

ACKNOWLEDGMENTS

This work was funded by grants from the National Institutes of Health (NS065547-01 to D.H.G. and 1K01 CA118425 to K.M.H.). R.H.F.B. was supported by a National Institute of General Medical Sciences Training Grant (GM: 007067) and a pre-doctoral Young Investigator Award from the Children’s Tumor Foundation. We thank the Alvin J. Siteman Cancer Center for the use of the Siteman Flow Cytometry Core (NCI Cancer Center Support Grant #P30 CA91842). The Rb antibody was obtained from the Developmental Studies Hybridoma Bank, created by the NICHD of the NIH and maintained at The University of Iowa (Department of Biology, Iowa City, IA 52242).

DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST

The authors report no potential conflicts of interest.

AUTHOR CONTRIBUTIONS

R.H.F.B.: Conception and design, collection and assembly of data, data analysis and interpretation, manuscript writing, final approval of manuscript; K.M.H.: Provision of H-RasG12V mouse, final approval of manuscript; D.H.G.: Conception and design, financial support, administrative support, data analysis and interpretation, manuscript writing, final approval of manuscript.

REFERENCES

2 Temple S, Alvarez-Buylla A. Stem cells in the adult mammalian central nervous system.
5 Luskin MB, Pearlman AL, Sanes JR. Cell lineage in the cerebral cortex of the mouse studied in vivo and in vitro with a
52 Darley RI, Pears LN, Omidvar N et al. Protein kinase C mediates mutant N-Ras induced developmental abnormalities in normal human erythroid cells. Blood. 2002;100:4185-4192.
54 Li Q, Haigis KM, McDaniel A et al. Hematopoiesis and leukemogenesis in mice
62 Hancock JF, Paterson H, Marshall CJ. A polybasic domain or palmitoylation is required in addition to the CAAX motif to localize p21ras to the plasma membrane. Cell. 1990;63:133-139.
Figure 1. Activated K-Ras expression in NSCs leads to increased gliogenesis in vivo. At PN18, K-Ras^{BLBP}, but not H-Ras^{BLBP} or N-Ras^{BLBP}, mice harbor an increased percentage of astrocytes in the brainstem as quantified using the (A) GFAP (1.8-fold, **p<0.01) and (B) S100β (1.2-fold) astrocyte markers. Representative images are shown in the right panels (20x, scale bar=50μm). There were no changes in the percentages of (C) APC^{+} oligodendrocytes or (D) NeuN^{+} neurons in the three Ras^{BLBP} genotypes relative to littermate controls. Error bars represent the standard errors of the mean.
Figure 2. Activated K-Ras expression does not affect NSC multi-lineage differentiation. (A) Ras activation (Ras-GTP) is increased in all three Ras* NSC populations following Cre expression. (B) Differentiation of adherent NSC cultures demonstrates that K-Ras*, but not H-Ras* or N-Ras*, expressing NSCs have a greater number of GFAP+ astrocytes compared to controls (1.8-fold, ***p<0.001). Graphs from representative experiments are shown with representative images included (GFAP+ (green) and DAPI+ (blue), 20x, scale bar=50µm). (C) K-Ras*, but not H-Ras* or N-Ras*, expressing NSCs also give rise to more total DAPI+ cells relative to control cells (1.8-fold, ***p<0.001). (D) K-Ras*, H-Ras*, and N-Ras*-expressing NSCs have similar percentages of GFAP+ astrocytes relative to controls. Error bars represent the standard errors of the mean.
Figure 3. Activated K-Ras expression increases NSC proliferation during differentiation. (A) EdU labeling at day 1 and day 5 post-plating was employed to determine whether Sox2+ NSCs or GFAP+ astrocytes proliferate during NSC differentiation. (B) K-Ras* expressing cells proliferate 7.2-fold more than control cells at day 1 (**p<0.001). (C) These EdU+ proliferating cells are exclusively Sox2+ NSCs, and not GFAP+ astrocytes. (D) There is no significant difference in the percentage of Sox2+ cells between K-Ras* and control NSCs; however, there was a decrease in the percentage of GFAP+ astrocytes in K-Ras* expressing cells relative to controls. (E) At day 5, K-Ras* expressing cells proliferate 2.2-fold more than controls (*p<0.05). (F) No differences in proliferating NSCs (Sox2+) and astrocytes (GFAP+) in K-Ras* expressing cells relative to control cells were observed. (G) There was a 2.1-fold increase in the percentage of Sox2+ cells in K-Ras* expressing NSCs compared to control NSCs (**p<0.01), while there was no difference in the percentage of GFAP+ astrocytes. All graphs are from the same representative experiment; error bars represent the standard errors of the mean. Representative images for (D) and (G) appear below their respective graphs (20x, scale bar=50µm). Arrowheads mark representative EdU+/Lineage+ double-positive cells, arrows mark cells positive for GFAP alone, and asterisks (*) mark cells positive for EdU alone.
Figure 4. Activated K-Ras expression increases NSC proliferation in vitro. (A) K-Ras*, but not H-Ras* or N-Ras*, expressing NSCs have increased growth as measured by direct cell counting after five days in culture (2.3-fold, ***p<0.001). (B) K-Ras*, but not H-Ras* or N-Ras*, expressing neurospheres have an increased percentage of Ki67+ cells relative to controls (1.6-fold, ***p<0.001). Representative neurospheres are shown to the left of the graph (DAPI+ (blue) and Ki67+ (red), 20x, scale bar=50µm). Graphs are representative of multiple independent experiments. (C, D) Flow cytometry of fixed propidium iodide (PI)-stained NSCs demonstrates an increased percentage of K-Ras*-expressing NSCs in S phase (+3.6%) and G2/M phase (+2.6%) than in G0/G1 phase of the cell cycle (-4.6%) compared to control cells (*p<0.05, ***p<0.001). (C) Shows one representative experiment, while (D) includes the data from four independent experiments. Error bars represent the standard errors of the mean. (E, F) Flow cytometry of live NSCs shows no difference in the percentage of live (propidium iodide, annexin V) versus apoptotic (annexin V+) cells. (E) Shows one representative experiment, while (F) includes the data from all four independent experiments. Error bars represent the standard errors of the mean. (G) Proposed model in which activated K-Ras expression increases NSC proliferation (1.7-fold by direct cell count, 1.6-fold by Ki67+ staining of neurospheres) and astrocyte numbers (1.8-fold).

Figure 5. *K-Ras*<sup>BLBP</sup> mice have more neuroglial progenitors during brain development. (A) At embryonic day 12.5 (E12.5), *K-Ras*<sup>BLBP</sup> mice have 2-fold more Sox2<sup>+</sup> NSCs per 0.1mm<sup>2</sup> in the developing hindbrain (the future site of the pons) relative to littermate controls (**p<0.01). Representative images are shown at the right, with the Sox2<sup>+</sup> cells in green and the dashed line denoting the ventricular surface (20x, scale bar=50μm). (B) At postnatal day 1 (PN1), there is no difference in the percentage of Sox2<sup>+</sup> NSCs in the brainstem, however, (C) *K-Ras*<sup>BLBP</sup> mice have 1.9-fold more Olig2<sup>+</sup> glial progenitor cells compared to littermate controls (NS=not significant, ***p<0.001). Representative images appear to the right of their respective graphs with arrowheads identifying Sox2<sup>+</sup> or Olig2<sup>+</sup> nuclei (red), respectively. DAPI (blue) marks total cells (20x, scale bar=50μm). Error bars represent the standard errors of the mean.
Figure 6. Activated K-Ras regulates NSC proliferation in a Raf-dependent, but Mek-independent, manner. (A) In K-Ras*-expressing NSCs, K-Ras activity is 30-fold higher than that observed in control NSCs as determined using a commercial Ras-GTP affinity assay (n=3, ***p<0.001). (B) K-Ras*-induced NSC hyperproliferation is reduced to control levels (indicated by the horizontal dashed line) following pharmacological inhibition of Ras using the GGTI-286 geranylgeranyltransferase inhibitor (6.5µM) (**p<0.05). Western blotting of Erk activity (above) was used as a readout for decreased Ras signaling in GGTI-286-treated NSCs. (C) Expression of a dominant-negative K-Ras molecule (dnK-Ras\(^{N17}\)) reduced K-Ras*-induced NSC hyperproliferation to control levels. IRES-GFP (GFP) and dnK-Ras\(^{N17}\)-IRES-GFP (dnK-Ras\(^{T26}\)) virus infection of neurospheres was confirmed by GFP expression in the images at the right (10x, scale bar=25µm). (D) K-Ras*-induced NSC hyperproliferation is reduced to control levels following pharmacological inhibition of Raf activity (AZ628, 200nM) (**p<0.01). (E) The downstream Ras effector, Erk1/2 (p-Erk\(^{T202/Y204}\)), is hyperactivated in K-Ras*-expressing NSCs relative to controls. However, there is no reduction in K-Ras*-induced NSC hyperproliferation following pharmacological inhibition with the Mek inhibitors (F) PD0325901 (PD901, 2nM) or (G) MEK162 (50nM) (NS=not significant). Error bars represent the standard errors of the mean.
Figure 7. Activated K-Ras regulates NSC proliferation in a Raf- and Rb-dependent manner. (A) Raf-1 immunoprecipitation reveals that Rb binds to Raf-1 in K-Ras*-expressing NSCs. (B) The small molecule inhibitor RRD-251 reduces K-Ras*-induced NSC hyperproliferation to control levels, as measured by direct cell counting (**p<0.01). Error bars represent the standard errors of the mean. (C) Proposed model for K-Ras*-mediated regulation of NSC proliferation. Active K-Ras-GTP activates Raf by binding to the Ras-binding domain (RBD). This leads to subsequent Rb binding to and inhibition of Rb activity, culminating in increased cell cycle progression (proliferation).